{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:33:10Z","timestamp":1793665990319,"version":"4.5.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ajo.2013.05.016","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T15:16:54Z","timestamp":1372951014000},"page":"731-736.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension"],"prefix":"10.1016","volume":"156","author":[{"given":"Hidenobu","family":"Tanihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Araie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ajo.2013.05.016_bib1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJM199111143252004","article-title":"Racial differences in the cause-specific prevalence of blindness in east Baltimore","volume":"325","author":"Sommer","year":"1991","journal-title":"N Engl J Med"},{"issue":"9774","key":"10.1016\/j.ajo.2013.05.016_bib2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","volume":"377","author":"Quigley","year":"2011","journal-title":"Glaucoma. Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2013.05.016_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14728214.2011.563733","article-title":"Current and emerging medical therapies in the treatment of glaucoma","volume":"16","author":"Bagnis","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.ajo.2013.05.016_bib4","first-page":"137","article-title":"Effects of Rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure and outflow facility","volume":"42","author":"Honjo","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2013.05.016_bib5","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.exer.2005.07.006","article-title":"Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells","volume":"82","author":"Koga","year":"2006","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.ajo.2013.05.016_bib6","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1167\/iovs.11-8018","article-title":"The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells","volume":"53","author":"Kameda","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2013.05.016_bib7","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1167\/iovs.05-1617","article-title":"Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys","volume":"48","author":"Tokushige","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2013.05.016_bib8","first-page":"1029","article-title":"Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632","volume":"42","author":"Rao","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2013.05.016_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/archophthalmol.2007.76","article-title":"Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers","volume":"126","author":"Tanihara","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2013.05.016_bib10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"Ocular hypotensive effect of the rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2013.05.016_bib11","unstructured":"Tanihara H, Inoue T, Yamamoto T, et\u00a0al. Phase 1 clinical trials of a selective rho kinase inhibitor, K-115. JAMA Ophthalmol. Forthcoming."}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413003346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939413003346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:07:55Z","timestamp":1757596075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939413003346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0002939413003346"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2013.05.016","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2013.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}